Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) T.ATE

Alternate Symbol(s):  ATBPF

Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


TSX:ATE - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Wallace's latest paper ...
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(55)
•••
Comment by StockingUp21on Jun 02, 2021 11:26am
62 Views
Post# 33310755

RE:RE:RE:RE:RE:RE:Wallace's latest paper ...

RE:RE:RE:RE:RE:RE:Wallace's latest paper ...

so why invest here if old technology patents are worthless? 


Actuarial wrote: If you wait for perfect drugs, you died long time ago.lol

StockingUp21 wrote:

so how is this good? Short term good, long term very bad? 


 

Actuarial wrote: To honest, I don't know. ATE might create something with H2S+NO+CO to crash NOSH, LOL, but who knows. Everyone want a cut in the NSAIDs market as it is so huge.

 

MrMugsy wrote:
Actuarial wrote: The bad news is, antibe doesn't own NOSH-NSAIDs patent. The good news is, after amalgamation, Antibe own the original H2S patent. So NOSH-NASIDs either pay antibe to acquire the H2S platform if NOSH wins. Or, wait for H2S patent expires, which would be similar to antibe with Bayer's naproxen.
MrMugsy wrote: Does look like NOSH-ASA is the potential product running in parallel to ATB-346 (reading between the lines).  Makes sense that we have a hybrid H2S and NO gaseous mediators running with Aspriin as the active ingredient.

If NOSH-ASA wins out over 340, maybe we are heading to a future of hybrids (IMO).

 


Can ATE create similar ... next generation multi-gaseious mediator release ?

 

 




<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities